Regulatory Focus™ > News Articles > 2021 > 8 > Recon: NYT says Abbott destroyed COVID tests when sales dwindled; Woodcock out of running for FDA co

Recon: NYT says Abbott destroyed COVID tests when sales dwindled; Woodcock out of running for FDA commissioner?

Posted 20 August 2021 | By Kari Oakes 

Recon: NYT says Abbott destroyed COVID tests when sales dwindled; Woodcock out of running for FDA commissioner?

 
Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.
 
In Focus: US
  • Maker of Popular Covid Test Told Factory to Destroy Inventory (NYT)
  • Acting FDA Chief Janet Woodcock Ruled Out as Biden Nominee (Bloomberg)
  • Child Covid-19 hospitalizations soar, filling pediatric wings, data show (NBC)
  • White House: More than one million vaccine doses administered in past 24 hours (The Hill)
  • Three senators announce positive COVID-19 tests in single day (The Hill)
  • That $56,000 Drug? Blame Medicare. (NYT)
  • House Democrats press insulin manufacturers for lower prices (The Hill)
In Focus: International
  • WHO: Call for experts to join Scientific Advisory Group for the Origins of Novel Pathogens (WHO)
  • 'Moderna Of China' Gets $700m Injection As Investors Bet Big On Domestic mRNA Vaccines (Scrip)
  • Dealmaking and bispecifics cut trail to IPO for Y-Biologics (Biocentury)
  • UK approves rollout of ‘first of its kind’ Covid antibody treatment (MHRA) (Guardian) (BioPharma Reporter)
Coronavirus Pandemic
  • Moderna secures extended vaccine supply with Canada, sees regulatory advances (Biopharma Reporter)
  • AstraZeneca to seek regulatory approval for COVID-19 prevention antibody (Biopharma Reporter) (Fierce) (Endpoints)
  • Fauci says U.S. is expanding Covid vaccine manufacturing to donate more doses to the world (CNBC)
  • USP Expands Global COVID-19 Response to Tackle Substandard & Falsified Vaccines (USP)
  • J&J seeks nod for COVID-19 vaccine trial in Indian adolescents (Reuters)
Pharma & Biotech
  • J&J veteran Joaquin Duato to take over as chief executive (FT) (Biocentury)
  • Moderna is Launching Trials of Two mRNA Vaccines Against HIV (FDA News)
  • NICE Recommends First Treatment for Rare Blood Disorder (Rare Daily)
  • We asked our biopharma readers about their company's policies on vaccine mandates. Feelings are running strong (Endpoints)
  • More Than Advisers: Survey Shows FDA Advisory Committee Members Want More Power (FDA News)
  • After company protest, FDA agrees to review controversial drug to prevent premature birth (STAT)
  • Beckley raises $80 million for psychedelic drugs (C&EN)
  • Vigil Raises $90 Million to Advance Pipeline to Treat Neurodegenerative Diseases (Rare Daily)
  • EC nod for Astellas, FibroGen’s roxadustat for chronic kidney disease (PharmaTimes)
  • Fate's closely watched stem cell-derived NK program raises red flag over durability of response (Endpoints)
  • AstraZeneca's Alexion halts ALS trial on lack of efficacy (Reuters)
  • Despite upbeat tones from analysts, Fate Therapeutics' stock drops on blood cancer readout (Fierce)
  • Lilly separates a neuroscience research group (C&EN)
  • FDA Grants Fast Track Designation to Senhwa’s Silmitasertib to Treat Recurrent SHH Medulloblastoma (Rare Daily)
  • EC approves BMS cell therapy for multiple myeloma (PMLive)
  • UK’s NICE to revamp its processes to make access to medicines “fairer” (PMLive)
  • A new technology, based on a quirk of evolutionary biology, may be the next big thing for CRISPR (STAT)
  • Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (Nature Reviews Drug Discovery)
Medtech
  • Akili strikes $37.5M licensing deal for another game-based treatment (MedCity News)
  • Cardinal Health Recalls Argyle UVC Insertion Tray Due to Missing Instructions for Use for the Safety Scalpel N11 (FDA)
  • 3D-Printable Biomaterial Takes Shape for Tissue Scaffolds (MD+DI)
Government, Regulatory & Legal
  • NY Decries 'Brazen Gaslighting' By Endo's Opioid Attys (Law360)
  • Biotech co-founder settles accusations of faked research data (Fierce)
  • Judge Urges Attention to Individual Stories in Purdue Ch. 11 (Law360)
  • States Scurry Ahead of Saturday’s $26 Billion Opioid Settlement Deadline (FDA News)
  • E.D. Pa. Judge Dismisses All Claims in Sloppy IVC Filter Complaint (Drug & Device Law)
  • AbbVie, Janssen Win IP Fight Over Cancer Drug Imbruvica (Law360)
Regulatory Recon is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe.
 
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
 

 

© 2021 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe